Quantcast

Latest Venlafaxine Stories

2009-11-24 17:24:48

However, bupropion XL and mirtazapine can benefit people suffering from depression.

2009-08-25 12:45:55

The Institute for Quality and Efficiency in Health Care (IQWiG) was commissioned by the Federal Joint Committee (G-BA) to investigate whether patients with depression benefit from taking drugs belonging to the selective serotonin and norepinephrine reuptake inhibitor (SNRI) drug class.

9cd0ec926c17c31fbd62d0664ec854be1
2009-08-12 11:20:00

Researchers from the FDA released an analysis on Tuesday that showed people under age 25 who take antidepressants have a higher risk of suicide, but adults older than that do not.

2009-07-06 15:26:36

Combining antidepressant drugs with electroconvulsive therapy (ECT) does a better job of reducing symptoms of severe depression and causes less memory loss than using ECT alone, according to a new study by researchers at Wake Forest University School of Medicine and colleagues.

2009-06-02 10:53:00

Only 41 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources Patient-Flow Models Need to Take Into Account Effexor XR's More Frequent Use in Early Lines of Therapy Compared With Cymbalta WALTHAM, Mass., June 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that one third of surveyed psychiatrists and two...

2009-05-12 07:00:00

Use of Atypicals In Major Depression Treatment Is Growing, According to a New Report from Decision Resources Patient-Flow Forecasts Between Pristiq and Effexor XR Need to Take Into Account Reimbursement Hurdles WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Forest Laboratories' Lexapro is no longer the leading first-line agent of choice for the treatment of major...

2008-11-14 12:00:05

Lexicon Pharmaceuticals, a biopharmaceutical company, has successfully completed a second Phase I clinical trial of LX1032, an orally-delivered small molecule drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome.

2008-11-13 06:00:08

* Drug Candidate Will Advance to Phase 2 Clinical Trial in Carcinoid Patients * Potent Reduction in Serotonin Achieved * Drug Candidate Being Developed Under Fast Track Status From FDA THE WOODLANDS, Texas, Nov. 13, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.

2008-10-26 06:00:14

Auspex Pharmaceuticals has reported positive results from its Phase I clinical trial evaluating SD-254, a selective serotinin-norepinephrine reuptake inhibitor. Auspex is developing SD-254, a deuterium-substituted version of venlafaxine, for the treatment of major depressive disorder.


Word of the Day
saggar
  • A ceramic container used inside a fuel-fired kiln to protect pots from the flame.
The word 'saggar' may come from 'safeguard'.
Related